Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) stock gains by 32.32% in the current market trading session. Lixte Biotechnology Holdings is a clinical-stage pharmaceutical business devoted to developing medicines that would improve the treatment of a variety of cancers and other severe disorders.
>> 7 Top Picks for the Post-Pandemic Economy <<
What’s up with LIXT stock?
In models of small cell lung cancer, Lixte Biotechnology’s main clinical drug, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was found to improve the efficacy of components of conventional therapy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
- 3 Best Marijuana Stocks to Watch for in 2021
The paper’s corresponding author is Dr. Ravi Salgia, MD, Ph.D., Professor, and Chair of the Department of Medical Oncology and Therapeutics Research, and Arthur & Rosalie Kaplan Chair in Medical Oncology, City of Hope. He is also the main researcher for a newly started Phase 1b clinical study in which LB-100 is added to conventional carboplatin, etoposide, and atezolizumab regimen for patients with advanced small-cell lung cancer who are not treated before.
Lixte Biotechnology is funding the clinical investigation. These findings are of particular importance to Lixte since they not only provide a compelling justification for the newly launched clinical study of LB-100 with chemo-immunotherapy in SCLC, but they also add to prior preclinical findings.
Lixte’s CEO, John S. Kovach, commented that,
Dr. Salgia and his colleagues have conducted significant pre-clinical research on the aberrant molecular characteristics of SCLC and the impact of LB-100 on components of a conventional SCLC therapy regimen. When these cancer cells were treated to LB-100 alone or in combination with the medicines in this typical treatment regimen for this famously aggressive illness, they discovered several metabolic alterations linked with cell death.
In animal models, LB-100 has been shown to improve the efficacy of a number of anti-cancer medicines against a variety of human malignancies without increasing toxicity.
- LB-100 enhances the quantity of carboplatin that reaches the tumor cells without rising toxicity.
- LB-100 enhances the quantity of carboplatin that reaches the tumor cells without enhancing toxicity.
